By Danny Sullivan – Longevity.Technology –
Healthspan as a universal right, the need for new regulation, the age of mitochondrial therapies and 7 shifts to accelerate longevity.
As we reflect on some of the interviews we’ve conducted over the past 12 months, it’s apparent that the longevity field is finally starting to get to grips with some of the key issues that have limited its progress. From expanding “right to try” laws and how to pitch healthspan to governments, to the implications of the FDA’s first approval of a mitochondria-targeted therapy, we’ve spoken to a host of heavy hitters on the big topics. Here is a small selection.
